Maximum growth and survival of estrogen receptor-alpha positive breast cancer cells requires the Sin3A transcriptional repressor

BackgroundSin3A is an evolutionarily conserved transcriptional repressor which regulates gene expression as part of the multi-protein Sin3 repressive complex. It functions as a scaffold upon which proteins with enzymatic activity dock, including chromatin modifying histone deacetylases. Although regulation of transcription by Sin3A has been studied in detail, little is understood about the function of Sin3A in cancer cells. We previously showed that Sin3A is expressed in breast cancer cells and is a repressor of estrogen receptor-alpha (ERα, ESR1) gene expression. Here, we expand our previous studies to elucidate the function of Sin3A in the control of gene expression and growth of breast cancer cells.ResultsAnalysis of gene expression following knockdown of Sin3A revealed changes in both basal and regulated gene transcription. Genes of known importance in breast cancer and estrogen signaling, including ERBB2, PGR, MYC, CLU, and NCOA2, were among those identified as Sin3A-responsive. The mechanism of Sin3A action varied among genes and was found to be mediated through both HDAC1/2 -dependent and -independent activities. Loss of Sin3A inhibited breast cancer cell growth by increasing apoptosis without affecting cell cycle progression. Analysis of both ERα-positive and ERα-negative cell lines revealed that the effects of Sin3A on growth were cell-type specific, as Sin3A expression promoted maximum growth of only the ERα-positive cells, and, notably, Sin3A protein itself was increased by estrogen. Further gene expression experiments revealed that Sin3A repressed expression of key apoptotic genes, including TRAIL, TRAILR1, CASP10, and APAF1, in ERα-positive, but not ERα-negative, cell lines, which could provide a mechanistic explanation for cell-type differences in growth.ConclusionsThis study identifies Sin3A as a regulator of gene expression, survival, and growth in ERα-positive breast cancer cells. Sin3A regulates the transcription of genes involved in breast cancer and apoptosis and acts through multiple mechanisms not limited to histone deacetylase function. These findings reveal previously undescribed functions of Sin3A in breast cancer and provide evidence for an important role of this transcriptional repressor in ERα-positive tumor cell growth.

[1]  R. Eisenman,et al.  Mad-max transcriptional repression is mediated by ternary complex formation with mammalian homologs of yeast repressor Sin3 , 1995, Cell.

[2]  P. Chambon,et al.  Regulation of the estrogen receptor in MCF-7 cells by estradiol. , 1988, Molecular endocrinology.

[3]  V. Dixit,et al.  Death receptors: signaling and modulation. , 1998, Science.

[4]  Stuart L Schreiber,et al.  Histone Deacetylase Activity Is Required for Full Transcriptional Repression by mSin3A , 1997, Cell.

[5]  D. Green.  Apoptotic Pathways The Roads to Ruin , 1998, Cell.

[6]  R. Sutherland,et al.  Estrogen regulation of cell cycle progression in breast cancer cells 1 1 Proceedings of the 13th International Symposium of the Journal of Steroid Biochemistry & Molecular Biology “Recent Advances in Steroid Biochemistry & Molecular Biology” Monaco 25–28 May 1997. , 1998, The Journal of Steroid Biochemistry and Molecular Biology.

[7]  S. Kadam,et al.  A Positive Regulatory Role for the mSin3A-HDAC Complex in Pluripotency through Nanog and Sox2* , 2009, Journal of Biological Chemistry.

[8]  W. McGuire,et al.  The value of estrogen and progesterone receptors in the treatment of breast cancer , 1980, Cancer.

[9]  W. El-Deiry,et al.  Identification and Characterization of the Cytoplasmic Protein TRAF4 as a p53-regulated Proapoptotic Gene* , 2003, Journal of Biological Chemistry.

[10]  D. Goeddel,et al.  The TNF receptor 1-associated protein TRADD signals cell death and NF-κB activation , 1995, Cell.

[11]  Arul M. Chinnaiyan,et al.  The Receptor for the Cytotoxic Ligand TRAIL , 1997, Science.

[12]  E. Alarid,et al.  Temporal variation in estrogen receptor-α protein turnover in the presence of estrogen , 2008 .

[13]  Clifford A. Meyer,et al.  Genome-wide analysis of estrogen receptor binding sites , 2006, Nature Genetics.

[14]  Andrew G. Clark,et al.  Genomic Analyses of Transcription Factor Binding, Histone Acetylation, and Gene Expression Reveal Mechanistically Distinct Classes of Estrogen-Regulated Promoters , 2007, Molecular and Cellular Biology.

[15]  Xiaodong Wang,et al.  Apaf-1, a Human Protein Homologous to C. elegans CED-4, Participates in Cytochrome c–Dependent Activation of Caspase-3 , 1997, Cell.

[16]  S. Wong.  Emerging treatment combinations: integrating therapy into clinical practice. , 2009, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[17]  Johan Eide,et al.  Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[19]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[20]  I. Herskowitz,et al.  Activation of the yeast HO gene by release from multiple negative controls , 1987, Cell.

[21]  D. Stillman,et al.  Both positive and negative regulators of HO transcription are required for mother-cell-specific mating-type switching in yeast , 1987, Cell.

[22]  Barry Komm,et al.  Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. , 2003, Endocrinology.

[23]  William Rostène,et al.  Hormonal regulation of apoptosis in breast cells and tissues , 2000, Steroids.

[24]  S. V. van Heeringen,et al.  Genetic Identification of a Network of Factors that Functionally Interact with the Nucleosome Remodeling ATPase ISWI , 2008, PLoS genetics.

[25]  D. Reinberg,et al.  Histone Deacetylases and SAP18, a Novel Polypeptide, Are Components of a Human Sin3 Complex , 1997, Cell.

[26]  David D. Smith,et al.  A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Metastatic Breast Cancer: A California Cancer Consortium Study , 2008, Clinical Cancer Research.

[27]  W. McGuire,et al.  Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[29]  P. Gottlieb,et al.  Identification and characterization of Smyd2: a split SET/MYND domain-containing histone H3 lysine 36-specific methyltransferase that interacts with the Sin3 histone deacetylase complex , 2006, Molecular Cancer.

[30]  D. Goeddel,et al.  The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. , 1995, Cell.

[31]  W. Herr,et al.  Human Sin3 deacetylase and trithorax-related Set1/Ash2 histone H3-K4 methyltransferase are tethered together selectively by the cell-proliferation factor HCF-1. , 2003, Genes & development.

[32]  S. Ellison-Zelski,et al.  Repression of ESR1 through Actions of Estrogen Receptor Alpha and Sin3A at the Proximal Promoter , 2009, Molecular and Cellular Biology.

[33]  Karl Ekwall,et al.  Sin3: a flexible regulator of global gene expression and genome stability , 2004, Current Genetics.

[34]  H. Chun,et al.  Caspase-10 is an initiator caspase in death receptor signaling , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[35]  S. Srinivasula,et al.  Cytochrome c and dATP-Dependent Formation of Apaf-1/Caspase-9 Complex Initiates an Apoptotic Protease Cascade , 1997, Cell.

[36]  Michael L. Blackburn,et al.  An ERG (ets-related gene)-associated histone methyltransferase interacts with histone deacetylases 1/2 and transcription co-repressors mSin3A/B. , 2003, The Biochemical journal.

[37]  R. DePinho,et al.  mSin3A corepressor regulates diverse transcriptional networks governing normal and neoplastic growth and survival. , 2005, Genes & development.

[38]  H. D. Liggitt,et al.  The mSin3A Chromatin-Modifying Complex Is Essential for Embryogenesis and T-Cell Development , 2005, Molecular and Cellular Biology.

[39]  L. Kristensen,et al.  Epigenetics and cancer treatment. , 2009, European journal of pharmacology.

[40]  S. Gibson,et al.  BNIP3 subfamily BH3-only proteins: mitochondrial stress sensors in normal and pathological functions , 2008, Oncogene.

[41]  Carlos S. Moreno,et al.  MTA3, a Mi-2/NuRD Complex Subunit, Regulates an Invasive Growth Pathway in Breast Cancer , 2003, Cell.

[42]  R. Kingston,et al.  Purification and characterization of mSin3A-containing Brg1 and hBrm chromatin remodeling complexes. , 2001, Genes & development.

[43]  F. Stossi,et al.  Whole-Genome Cartography of Estrogen Receptor α Binding Sites , 2007, PLoS genetics.

[44]  M. Stallcup,et al.  GRIP1, a novel mouse protein that serves as a transcriptional coactivator in yeast for the hormone binding domains of steroid receptors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[45]  Colin A. Johnson,et al.  Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex , 1998, Nature.

[46]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[47]  S. Marsters,et al.  Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family* , 1996, The Journal of Biological Chemistry.

[48]  Hye-Jin Park,et al.  TOPORS functions as a SUMO-1 E3 ligase for chromatin-modifying proteins. , 2007, Journal of proteome research.

[49]  T. Burns,et al.  Bnip3L is induced by p53 under hypoxia, and its knockdown promotes tumor growth. , 2004, Cancer cell.

[50]  A. Roopra,et al.  Transcriptional Repression by Neuron-Restrictive Silencer Factor Is Mediated via the Sin3-Histone Deacetylase Complex , 2000, Molecular and Cellular Biology.

[51]  M. MacFarlane.  TRAIL-induced signalling and apoptosis. , 2003, Toxicology letters.

[52]  S. Berger,et al.  A Feed-Forward Repression Mechanism Anchors the Sin3/Histone Deacetylase and N-CoR/SMRT Corepressors on Chromatin , 2006, Molecular and Cellular Biology.

[53]  I. Morison,et al.  Targeting the Apoptosome for Cancer Therapy , 2009, Clinical Cancer Research.

[54]  Xiaoyong Yang,et al.  Recruitment of O-GlcNAc Transferase to Promoters by Corepressor mSin3A Coupling Protein O-GlcNAcylation to Transcriptional Repression , 2002, Cell.

[55]  P. Munster,et al.  Clinical and Biological Effects of Valproic Acid as a Histone Deacetylase Inhibitor on Tumor and Surrogate Tissues: Phase I/ii Trial of Valproic Acid and Epirubicin/fec Cancer Therapy: Clinical , 2022 .

[56]  L. Stephens,et al.  Metastasis Tumor Antigen Family Proteins during Breast Cancer Progression and Metastasis in a Reliable Mouse Model for Human Breast Cancer , 2006, Clinical Cancer Research.

[57]  Nobuyoshi Shimizu,et al.  Decreased expression of the SIN3A gene, a candidate tumor suppressor located at the prevalent allelic loss region 15q23 in non-small cell lung cancer. , 2008, Lung cancer.

[58]  T. Kouzarides,et al.  Transcriptional repression by the insulator protein CTCF involves histone deacetylases. , 2000, Nucleic acids research.

[59]  A. Levine,et al.  Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. , 1999, Genes & development.

[60]  V. Jordan,et al.  Basic guide to the mechanisms of antiestrogen action. , 1998, Pharmacological reviews.

[61]  A. Zelent,et al.  Interference with Sin3 function induces epigenetic reprogramming and differentiation in breast cancer cells , 2010, Proceedings of the National Academy of Sciences.

[62]  E. Alarid,et al.  Temporal variation in estrogen receptor-alpha protein turnover in the presence of estrogen. , 2008, Journal of molecular endocrinology.

[63]  Debashis Ghosh,et al.  EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[64]  T. Eberlein.  A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer , 2006 .